David Belford
Managing Director
AbRegen
Australia
Biography
Dr David Belford is the Managing Director of AbRegen. Dr Belford has over 20 years experience in scientific research and translational activities. After pursing a research career within the Commonwealth Scientific and Industrial Research Organisation and Cooperative Research Centre for Tissue Growth and Repair, where he was Leader of the Wound Healing Program, Dr Belford joined the start-up company GroPep Pty Ltd. He was a member of the senior management team that took GroPep Ltd to its successful IPO, and as Medical Director subsequently established the company’s product development capabilities, including preclinical, analytical, regulatory and clinical activities. Following the acquisition of GroPep by Novozymes A/S (for ~AUD$100M), he took a role as a Business Development Manager with the Novozymes’ Copenhagen-based Business Development and Acquisitions group before accepting the role as the foundation Director of Research for the Wound Management Innovation Cooperative Research Centre. Dr Belford holds a first class honours degree in science and a medical degree from the Flinders University of South Australia, and a PhD from the John Curtin School of Medical Research (Australian National University).
Research Interest
Scientific research
